9/5/07 S.F. DO NOT ENTER

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (Currently amended): A compound of structural formula I:



(I)

or a pharmaceutically acceptable salt thereof, wherein;

R^1 is selected from:

(1) C_{1-10}alkyl,

(2) C_{3-10}cycloalkyl, and

(3) aryl,

wherein alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, and aryl optionally is substituted with one, two, three or four substituents independently selected from R^b;

R^2 is selected from:

(1) C_{3-10}cycloalkyl,

(2) cycloheteroalkyl,

(3) aryl,

(4) heteroaryl,

(5) $-OR^d$,

(6) $-NR^cR^d$, and

(7) $-CO_2R^d$,

wherein each cycloalkyl, cycloheteroalkyl, aryl and heteroaryl are optionally substituted on a carbon or nitrogen atom with one, two, three or four substituents independently selected from R^b;

R^3 is C_{1-4}alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;

R^6 is selected from:

(1) hydrogen,
(2) C_{1-4}alkyl,
(3) C_{2-4}alkenyl,
(4) C_{2-4}alkynyl,
(5) $-OR^d$,
(6) halogen,
(7) -CN,
(8) $-NR^cR^d$,

wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substituents independently selected from R^a

Ar^1 is aryl, optionally substituted with one, or two~~, or three~~ groups independently selected from R^b; each R^a is independently selected from:

(1) $-OR^c$,
(2) $-NR^cS(O)_mR^d$,
(3) $-NO_2$,
(4) halogen,
(5) $-S(O)_mR^c$,
(6) $-SR^c$,
(7) $-S(O)_2OR^c$,
(8) $-S(O)_mNR^cR^d$,
(9) $-NR^cR^d$,
(10) $-O(CR^eR^f)_nNR^cR^d$,
(11) $-C(O)R^c$,
(12) $-CO_2R^c$,
(13) $-CO_2(CR^eR^f)_nCONR^cR^d$,
(14) $-OC(O)R^c$,
(15) -CN,
(16) $-C(O)NR^cR^d$,
(17) $-NR^cC(O)R^d$,
(18) $-OC(O)NR^cR^d$,
(19) $-NR^cC(O)OR^d$,
(20) $-NR^cC(O)NR^cR^d$,
(21) $-CR^c(N\text{-}OR^d)$,
(22) CF_3,
(23) $-OCF_3$,
(24) C_{3-8}cycloalkyl,

(25) cycloheteroalkyl, and

(26) oxo;

each R^b is independently selected from:

(1) R^a,

(2) C_{1-10}alkyl,

(3) C_{3-8}cycloalkyl,

(4) cycloheteroalkyl,

(5) aryl,

(6) arylC_{1-4}alkyl,

(7) heteroaryl, and

(8) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, and heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with -OR^c, NR^cR^d, or -$C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,

(2) C_{1-10}alkyl,

(3) C_{2-10} alkenyl,

(4) C_{2-10}alkynyl,

(5) cycloalkyl,

(6) cycloalkyl-C_{1-10}alkyl,

(7) cycloheteroalkyl,

(8) cycloheteroalkyl-C_{1-10} alkyl;

(9) aryl,

(10) heteroaryl,

(11) aryl-C_{1-10}alkyl, and

(12) heteroaryl-C_{1-10}alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;

R^e and R^f are independently selected from:

(1) hydrogen,

(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) C_{2-10}alkynyl,
(5) cycloalkyl,
(6) cycloalkyl-C_{1-10} alkyl,
(7) cycloheteroalkyl,
(8) cycloheteroalkyl-C_{1-10} alkyl,
(9) aryl,
(10) heteroaryl,
(11) arylC_{1-10} alkyl, and
(12) heteroarylC_{1-10} alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each R^g is independently selected from

(1) C_{1-10}alkyl,
(2) C_{3-8}cycloalkyl,
(3) cycloheteroalkyl,
(4) aryl,
(5) arylC_{1-4}alkyl,
(6) heteroaryl,
(7) heteroarylC_{1-4}alkyl,
(8) $-S(O)_mR^e$,
(9) $-C(O)R^e$,
(10) $-CO_2R^e$,
(11) $-CO_2(CR^eR^f)_nCONR^eR^f$, and
(12) $-C(O)NR^eR^f$;

each R^h is independently selected from:

(1) C_{1-10}alkyl,
(2) C_{3-8}cycloalkyl,
(3) cycloheteroalkyl,
(4) aryl,
(5) arylC_{1-4}alkyl,
(6) heteroaryl,
(7) heteroarylC_{1-4}alkyl,
(8) $-OR^e$,
(9) $-NR^eS(O)_mR^f$,

(10) $-S(O)_mR^e$,

(11) $-SR^e$,

(12) $-S(O)_2OR^e$,

(13) $-S(O)_mNR^eR^f$,

(14) $-NR^eR^f$,

(15) $-O(CR^eR^f)_nNR^eR^f$,

(16) $-C(O)R^e$,

(17) $-CO_2R^e$,

(18) $-CO_2(CR^eR^f)_nCONR^eR^f$,

(19) $-OC(O)R^e$,

(20) -CN,

(21) $-C(O)NR^eR^f$,

(22) $-NR^eC(O)R^f$,

(23) $-OC(O)NR^eR^f$,

(24) $-NR^eC(O)OR^f$,

(25) $-NR^eC(O)NR^eR^f$,

(26) CF_3, and

(27) $-OCF_3$,

m is selected from 1 and 2; and

n is selected from 1, 2, and 3;

provided that when R^1 and R^2 are unsubstituted aryl or unsubstituted heteroaryl, and R^3 is hydrogen or C_{1-4} alkyl, then Ar^1 is substituted with at least one R^b substituent; and

provided that when R^1 is selected from the group consisting of unsubstituted phenyl, *para*-chlorophenyl or *para*–methoxy phenyl, R^2 is unsubstituted phenyl, and R^3 is $-CH_3$, then Ar^1 is not unsubstituted phenyl, *ortho*—CO_2H monosubstituted phenyl, or 3,4-dimethoxy phenyl.

Claim 2 (Previously presented): The compound according to Claim 1 wherein:

R^1 is selected from:

(1) C_{1-10}alkyl,

(2) C_{3-10}cycloalkyl, and

(3) aryl,

wherein alkyl is optionally substituted with one, two, three or four substituents independently selected from R^a, and each cycloalkyl, and aryl optionally is substituted with one, two, three or four substituents independently selected from R^b;

R^2 is selected from:

(1) C_{3-10}cycloalkyl,

(2) cycloheteroalkyl,

(3) aryl,

(4) heteroaryl,

(5) $-OR^d$,

(6) $-NR^cR^d$, and

(7) $-CO_2R^d$,

wherein each cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl are optionally substituted with one, two, three or four substituents independently selected from R^b;

or a pharmaceutically acceptable salt thereof.

Claim 3 (Currently amended): The compound according to Claim 2 wherein:

Ar^1 is selected from:

(1) phenyl, and

(2) naphthyl,

each optionally substituted with one, or two~~, or three~~ groups independently selected from R^b;

or a pharmaceutically acceptable salt thereof.

Claim 4 (Currently amended): The compound according to Claim 3 wherein:

R^3 is C_{1-4}alkyl, optionally substituted with one to four substituents independently selected from R^a;

R^6 is selected from:

(1) hydrogen,

(2) methyl,

(3) hydroxyl,

(4) halogen, and

(5) -CN,

wherein methyl is optionally substituted with one to three R^a substituents;

Ar^1 is selected from:

(1) phenyl, and

(2) naphthyl,

each optionally substituted with one, or two~~, or three~~ groups independently selected from R^b;

each R^a is independently selected from:

(1) -OR^c,
(2) halogen,
(3) -$S(O)_mR^c$,
(4) -SR^c,
(5) -$S(O)_2OR^c$,
(6) -$S(O)_mNR^cR^d$,
(7) -NR^cR^d,
(8) -$C(O)R^c$,
(9) -CO_2R^c,
(10) -CN,
(11) -$C(O)NR^cR^d$,
(12) CF_3,
(13) -OCF_3,
(14) C_{3-8}cycloalkyl,
(15) cycloheteroalkyl, and
(16) oxo;

each R^b is independently selected from:

(1) R^a,
(2) C_{1-10}alkyl,
(3) cycloheteroalkyl,
(4) aryl,
(5) arylC_{1-4}alkyl,
(6) heteroaryl, and
(7) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with -OR^c, NR^cR^d, or -$C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) cycloalkyl,
(4) cycloheteroalkyl,
(5) aryl,
(6) heteroaryl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-R^g,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;

or a pharmaceutically acceptable salt thereof.

Claim 5 (Previously presented): The compound according to Claim 4 wherein:

R^1 is phenyl, optionally substituted with one to four substituents independently selected from R^b; and

R^2 is independently selected from:

(1) phenyl, and

(2) pyridyl,

optionally substituted with one to four substituents independently selected from R^b;

R^3 is C_{1-4}alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;

R^6 is selected from:

(1) hydrogen,

(2) methyl,

(3) hydroxyl,

(4) halogen, and

(5) –CN;

each R^a is independently selected from:

(1) -OR^c,

(2) halogen,

(3) -$S(O)_mR^c$,

(4) -NR^cR^d,

(5) -$C(O)R^c$,

(6) -CO_2R^c, and

(7) oxo;

or a pharmaceutically acceptable salt thereof.

Claim 6 (Original): The compound according to Claim 5 wherein:

R^1 and R^2 are independently selected from:

(1) phenyl,

(2) 4-fluorophenyl,

(3) 2-chlorophenyl,

(4) 3-chlorophenyl,

(5) 4-chlorophenyl,
(6) 4-cyanophenyl,
(7) 4-methylphenyl,
(8) 4-isopropylphenyl,
(9) 4-biphenyl,
(10) 4-bromophenyl,
(11) 4-iodophenyl,
(12) 2,4-dichlorophenyl, and
(13) 2-chloro-4-fluorophenyl;

or a pharmaceutically acceptable salt thereof.

Claim 7 (Original): The compound according to Claim 6 wherein:
R^1 and R^2 are independently selected from phenyl and 4-chlorophenyl;
R^3 is methyl, wherein methyl is optionally substituted with one to three substituents independently selected from R^a;
or a pharmaceutically acceptable salt thereof.

Claim 8 (Currently amended): A compound selected from:

(1) *N*-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-3-chloro-2-naphthamide;
(2) 2-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(3) 3-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(4) 4-(1-tetrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(5) 2-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(6) 3-(1-(3,5-dimethyl-pyrazolyl))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(7) 4-(1-(pyrrolidin-2-one))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(8) 3-(1-(imidazolidin-2-one))-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(9) 4-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(10) 3-phenyl-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(11) 4-(1-pyrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(12) 2-(1-pyrazolyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(13) 4-(1-piperidinyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(14) 4-(2-formyl-phenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(15) 4-(2-hydroxymethyl-phenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;
(16) 4-(2-aminophenyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(17) 5-chloro-2-(2-(1-pyrrolyl)ethyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(18) 2-(2-phenylethyl)-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(19) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-naphthylene-2-carboxamide;

(20) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-naphthylene-1-carboxamide;

(21) N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(22) 2-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

(23) 3-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide; and

(24) 4-chloro-N-(2,3-bis(4-chlorophenyl)-1-methylpropyl)-benzamide;

or a pharmaceutically acceptable salt thereof.

Claim 9 (Currently amended): A compound of structural formula IA:



(IA)

or a pharmaceutically acceptable salt thereof, wherein;

R^1 is aryl, optionally substituted with one to four substituents independently selected from R^b;

R^2 is selected from:

(1) aryl, and

(2) heteroaryl,

wherein aryl and heteroaryl are optionally substituted on the carbon or nitrogen with one to four substituents independently selected from R^b;

R^3 is C_{1-4}alkyl,

wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;

Ar^1 is aryl, optionally substituted on the carbon or nitrogen with one, or two~~, or three~~ groups independently selected from R^b;

each R^a is independently selected from:

(1) $-OR^c$,

(2) $-NR^cS(O)_mR^d$,

(3) $-NO_2$,

(4) halogen,
(5) $-S(O)_mR^c$,
(6) $-SR^c$,
(7) $-S(O)_2OR^c$,
(8) $-S(O)_mNR^cR^d$,
(9) $-NR^cR^d$,
(10) $-O(CR^eR^f)_nNR^cR^d$,
(11) $-C(O)R^c$,
(12) $-CO_2R^c$,
(13) $-CO_2(CR^eR^f)_nCONR^cR^d$,
(14) $-OC(O)R^c$,
(15) -CN,
(16) $-C(O)NR^cR^d$,
(17) $-NR^cC(O)R^d$,
(18) $-OC(O)NR^cR^d$,
(19) $-NR^cC(O)OR^d$,
(20) $-NR^cC(O)NR^cR^d$,
(21) $-CR^c(N-OR^d)$,
(22) CF_3,
(23) $-OCF_3$,
(24) C_{3-8}cycloalkyl,
(25) cycloheteroalkyl, and
(26) oxo;

each R^b is independently selected from:

(1) R^a,
(2) C_{1-10}alkyl,
(3) C_{3-8}cycloalkyl,
(4) cycloheteroalkyl,
(5) aryl,
(6) arylC_{1-4}alkyl,
(7) heteroaryl, and
(8) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, and heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with $-OR^c$, NR^cR^d, or $-C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) C_{2-10}alkynyl,
(5) cycloalkyl,
(6) cycloalkyl-C_{1-10}alkyl,
(7) cycloheteroalkyl,
(8) cycloheteroalkyl-C_{1-10} alkyl;
(9) aryl,
(10) heteroaryl,
(11) aryl-C_{1-10}alkyl, and
(12) heteroaryl-C_{1-10}alkyl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,

each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;

R^e and R^f are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) C_{2-10} alkenyl,
(4) C_{2-10}alkynyl,
(5) cycloalkyl,
(6) cycloalkyl-C_{1-10} alkyl,
(7) cycloheteroalkyl,
(8) cycloheteroalkyl-C_{1-10} alkyl,
(9) aryl,
(10) heteroaryl,
(11) arylC_{1-10} alkyl, and
(12) heteroarylC_{1-10} alkyl, or

R^e and R^f together with the carbon to which they are attached form a ring of 5 to 7 members containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen;

each Rg is independently selected from

(1) C_{1-10}alkyl,

(2) C_{3-8}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl,

(7) heteroarylC_{1-4}alkyl,

(8) $-S(O)_mR^e$,

(9) $-C(O)R^e$,

(10) $-CO_2R^e$,

(11) $-CO_2(CR^eR^f)_nCONR^eR^f$, and

(12) $-C(O)NR^eR^f$;

each R^h is independently selected from:

(1) C_{1-10}alkyl,

(2) C_{3-8}cycloalkyl,

(3) cycloheteroalkyl,

(4) aryl,

(5) arylC_{1-4}alkyl,

(6) heteroaryl,

(7) heteroarylC_{1-4}alkyl,

(8) $-OR^e$,

(9) $-NR^eS(O)_mR^f$,

(10) $-S(O)_mR^e$,

(11) $-SR^e$,

(12) $-S(O)_2OR^e$,

(13) $-S(O)_mNR^eR^f$,

(14) $-NR^eR^f$,

(15) $-O(CR^eR^f)_nNR^eR^f$,

(16) $-C(O)R^e$,

(17) $-CO_2R^e$,

(18) $-CO_2(CR^eR^f)_nCONR^eR^f$,

(19) $-OC(O)R^e$,

(20) $-CN$,

(21) $-C(O)NR^eR^f$,

(22) $-NR^eC(O)R^f$,

(23) $-OC(O)NR^eR^f$,

(24) $-NR^eC(O)OR^f$,

(25) -$NR^eC(O)NR^eR^f$,
(26) CF_3, and
(27) $-OCF_3$,

m is selected from 1 and 2; and
n is selected from 1, 2, and 3;

provided that when R^1 and R^2 are unsubstituted aryl or unsubstituted heteroaryl, and R^3 is C_{1-4} alkyl, Ar^1 is substituted with at least one R^b substituent; and

provided that when R^1 is selected from the group consisting of unsubstituted phenyl, *para*-chlorophenyl or *para*–methoxy phenyl, R^2 is unsubstituted phenyl, and R^3 is $-CH_3$, Ar^1 is not unsubstituted phenyl, *ortho*–CO_2H monosubstituted phenyl, or 3,4-dimethoxy phenyl.

Claim 10 (Previously presented): The compound according to Claim 9 wherein:
R^1 is selected from phenyl and naphthyl, optionally substituted with one to four substituents independently selected from R^b;
and R^2 is selected from:
(1) phenyl,
(2) naphthyl, and
(3) pyridyl,
optionally substituted with one to four substituents independently selected from R^b;
or a pharmaceutically acceptable salt thereof.

Claim 11 (Currently amended): The compound according to Claim 10 wherein:
Ar^1 is selected from:
(1) phenyl, and
(2) naphthyl,
each optionally substituted with one, or two~~, or three~~ groups independently selected from R^b;
or a pharmaceutically acceptable salt thereof.

Claim 12 (Currently amended): The compound of claim 11 wherein:
R^3 is C_{1-4}alkyl,
wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;
Ar^1 is selected from:
(1) phenyl, and

(2) naphthyl,

each optionally substituted with one, or two~~, or three~~ groups independently selected from R^b;

each R^a is independently selected from:

(1) $-OR^c$,
(2) halogen,
(3) $-S(O)_mR^c$,
(4) $-SR^c$,
(5) $-S(O)_2OR^c$,
(6) $-S(O)_mNR^cR^d$,
(7) $-NR^cR^d$,
(8) $-C(O)R^c$,
(9) $-CO_2R^c$,
(10) -CN,
(11) $-C(O)NR^cR^d$,
(12) CF_3,
(13) $-OCF_3$,
(14) C_{3-8}cycloalkyl,
(15) cycloheteroalkyl, and
(16) oxo;

each R^b is independently selected from:

(1) R^a,
(2) C_{1-10}alkyl,
(3) cycloheteroalkyl,
(4) aryl,
(5) arylC_{1-4}alkyl,
(6) heteroaryl, and
(7) heteroarylC_{1-4}alkyl,

wherein alkyl, cycloalkyl, cycloheteroalkyl, heteroaryl are optionally substituted with oxo, and wherein aryl and heteroaryl are optionally substituted with $-OR^c$, NR^cR^d, or $-C(O)R^c$;

R^c and R^d are independently selected from:

(1) hydrogen,
(2) C_{1-10}alkyl,
(3) cycloalkyl,
(4) cycloheteroalkyl,
(5) aryl,
(6) heteroaryl, or

R^c and R^d together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,
or two -OR^c groups together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and N-Rg,
each R^c and R^d may be unsubstituted or substituted with one to three substituents selected from R^h;
or a pharmaceutically acceptable salt thereof.

Claim 13 (Previously presented): The compound according to Claim 12, wherein:
R^1 is phenyl optionally substituted with one to four substituents independently selected from R^b; and
R^2 is selected from:

(1) phenyl, and
(2) pyridyl,

optionally substituted with one to four substituents independently selected from R^b;
R^3 is C_{1-4}alkyl, wherein alkyl is optionally substituted with one to four substituents independently selected from R^a;
each R^a is independently selected from:

(1) -OR^c,
(2) halogen,
(3) -$S(O)_mR^c$,
(4) -NR^cR^d,
(5) -$C(O)R^c$,
(6) -CO_2R^c, and
(7) oxo;

or a pharmaceutically acceptable salt thereof.

Claim 14 (Original): The compound according to Claim 13, wherein:
R^1 and R^2 are independently selected from:

(1) phenyl,
(2) 4-fluorophenyl,
(3) 2-chlorophenyl,
(4) 3-chlorophenyl,
(5) 4-chlorophenyl,
(6) 4-cyanophenyl,
(7) 4-methylphenyl,
(8) 4-isopropylphenyl,

(9) 4-biphenyl,

(10) 4-bromophenyl,

(11) 4-iodophenyl,

(12) 2,4-dichlorophenyl, and

(13) 2-chloro-4-fluorophenyl;

or a pharmaceutically acceptable salt thereof.

Claim 15 (Original): The compound according to Claim 14 wherein:
R^1 and R^2 are independently selected from phenyl and 4-chlorophenyl;
R^3 is methyl, wherein methyl is optionally substituted with one to three substituents independently selected from R^a;
or a pharmaceutically acceptable salt thereof.

Claim 16 (Original): A composition comprising a compound according to Claim 1 and a pharmaceutically acceptable carrier.

Claim 17 (Original): A composition comprising a compound according to Claim 8 and a pharmaceutically acceptable carrier.

Claim 18 (Canceled)

Claim 19 (Canceled)

Claim 20 (Previously presented): A method of treating an eating disorder associated with excessive food intake selected from obesity, bulimia nervosa and compulsive eating disorders comprising administration of a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

Claims 21-23 (Canceled).

Claim 24 (Previously presented): The method according to Claim 20 wherein the eating disorder associated with excessive food intake is obesity.

Claims 25-30 (Canceled).

Claim 31 (Previously presented): A method of treating an eating disorder associated with excessive food intake selected from obesity, bulimia nervosa and compulsive eating disorders comprising administration of a therapeutically effective amount of a compound of Claim 8 to a patient in need of such treatment.

Claim 32 (Previously presented): The method according to Claim 31 wherein the eating disorder associated with excessive food intake is obesity.